Trials / Completed
CompletedNCT00692159
Study of TRC102 in Combination With Pemetrexed in Cancer Patients
Open Label Phase 1 Dose Finding Study of TRC102 in Combination With Pemetrexed in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Tracon Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being performed to evaluate the safety and tolerability of TRC102 in combination with Alimta. In addition to safety, this study will also evaluate pharmacokinetics and tumor response.
Detailed description
This study is being performed to evaluate the safety and tolerability of TRC102 in combination with Alimta. In addition to safety, this study will also evaluate pharmacokinetics and tumor response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TRC102 + pemetrexed | Oral TRC102 solution + IV pemetrexed |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2010-06-01
- Completion
- 2010-09-01
- First posted
- 2008-06-06
- Last updated
- 2010-09-10
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00692159. Inclusion in this directory is not an endorsement.